This work aimed to evaluate the flexibility of a novel pyrolytic carbon coated drug-eluting stent platform, which presents the peculiarity of deep sculptures realized on the stent's outer surface (reservoirs). Tacrolimus (TCR) or TCR/excipient mixtures were loaded into the reservoirs, and their permanence into stent's reservoirs was verified by an in vitro short-time release test in human blood. Moreover, the impact of the excipients on the TCR physical state and surface morphology of the reservoirs and the release kinetics were studied. The reservoirs resulted homogeneously filled. Upon exposure to blood, no loss of materials from reservoirs was observed, and the drug release after 15 min was negligible in all cases. The loading procedure caused the drug amorphization and, AFM revealed that the surfaces were smooth and homogeneous with the exception of the TCR/poloxamer 188 mixture where spatial oriented crystals were evident. Poly(N-vinyl pyrrolidone) improved the in vitro TCR release rate constants (K). Poly(methylmethacrylate) (PMM) significantly reduced the K value both in vitro and in vivo. Indeed, the in vivo drug concentrations in rabbit artery wall significantly decreased, decreasing the TCR/PMM ratio. The characteristics of the stent strut resulted suitable to load material with different physicochemical characteristics.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2009.08.004DOI Listing

Publication Analysis

Top Keywords

drug-eluting stent
8
reservoirs
6
sculptured drug-eluting
4
stent on-site
4
on-site delivery
4
delivery tacrolimus
4
tacrolimus work
4
work aimed
4
aimed evaluate
4
evaluate flexibility
4

Similar Publications

A dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo Stent (DTS) has been developed to enhance endothelization and capture endothelial progenitor cells; however, vessel responses following DTS implantation remain unclear. Therefore, we evaluated early- and mid-term intravascular characteristics of DTS using intravascular imaging modalities. This multicenter, prospective, observational study enrolled 88 patients (95 lesions) who underwent DTS (43 patients, 48 lesions) or sirolimus-eluting Orsiro stent (SES, 45 patients, 47 lesions) implantation.

View Article and Find Full Text PDF

Do drug-eluting stents increase non-cardiac mortality?

Can J Cardiol

January 2025

Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), CH-6900, Lugano, Switzerland; The Faculty of Biomedical Sciences, University of Italian Switzerland (USI), Lugano, Switzerland; University of Bern, Bern, Switzerland. Electronic address:

View Article and Find Full Text PDF

Background And Rationale: In-stent restenosis (ISR) remains the leading cause of treatment failure following percutaneous coronary intervention (PCI) with contemporary drug-eluting stents. Especially in small caliber coronary arteries, restenosis is common following PCI and represents a treatment challenge. Drug-coated balloons (DCB) are an attractive alternative to stents for treatment of both ISR and small vessel disease.

View Article and Find Full Text PDF

Biodegradable Stents in the Treatment of Arterial Stenosis.

J Clin Med

January 2025

Department of Accident and Emergency, Etlik City Hospital, Ankara 06170, Turkey.

Arterial diseases (ADs) are a significant health problem, with high mortality and morbidity rates. Endovascular interventions, such as balloon angioplasty (BA), bare-metal stents (BMSs), drug-eluting stents (DESs) and drug-coated balloons (DCBs), have made significant progress in their treatments. However, the issue has not been fully resolved, with restenosis remaining a major concern.

View Article and Find Full Text PDF

Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the standard treatment for patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). However, the optimal duration of DAPT remains debated due to the need to balance ischemic event reduction with bleeding risks. This study evaluates the efficacy and safety of ticagrelor monotherapy after short-duration DAPT (1-3 months) compared to extended DAPT, focusing on major bleeding and cardiovascular outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!